Seattle Genetics and Takeda Pharmaceutical complete enrolment for Phase III ECHELON-2 trial of ADCETRIS

Seattle Genetics and Takeda Pharmaceutical have completed patient enrolment for the Phase III ECHELON-2 clinical trial of ADCETRIS (brentuximab vedotin) to treat CD30-positive mature T-cell lymphoma (MTCL).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news